Showing results (1871-1880 of 2,232) with videos related to
Sort By:
Pageof 224
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 4, 2016
The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLCSi-Yang Liu, Lan-Ying Gou, An-Na Li, et al.JCI Insight|April 22, 2025
Rapamycin immunomodulation utilizes time-dependent alterations of lymph node architecture, leukocyte trafficking, and gut microbiomeLong Wu, Allison Kensiski, Samuel J Gavzy, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 2, 2015
Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non-small-cell Lung CancerSarayut L Geater, Chong-Rui Xu, Caicun Zhou, et al.JTO Clinical and Research Reports|September 30, 2021
Ceritinib Efficacy and Safety in Treatment-Naive Asian Patients With Advanced ALK-Rearranged NSCLC: An ASCEND-4 Subgroup AnalysisDaniel S W Tan, Sarayut Geater, Chong-Jen Yu, et al.Journal of the American Chemical Society|April 9, 2025
Heterogeneous-Interface-Induced Charge Redistribution Toward Fe-Based Polyanion Cathode for Advanced Sodium-Ion BatteriesZe-Lin Hao, Jin-Zhi Guo, Miao Du, et al.Physical Review Letters|September 26, 2025
Single-Chain Nanoparticles Break the Strength-Toughness-Processability Trilemma in Polymer GlassesLei Zhang, Xu-Ze Zhang, Rui Shi, et al.Advanced Science (Weinheim, Baden-Wurttemberg, Germany)|February 8, 2024
Transcriptomic Signature of 3D Hierarchical Porous Chip Enriched Exosomes for Early Detection and Progression Monitoring of Hepatocellular CarcinomaKezhen Yi, Yike Wang, Yuan Rong, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|November 9, 2024
Durvalumab Versus Chemotherapy as First-line Treatment for Metastatic NSCLC With Tumor PD-L1 Expression of 25% or Higher: Results From the Randomized Phase 3 PEARL StudyShun Lu, Lin Wu, Qiming Wang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 23, 2022
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK-Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN StudyBenjamin J Solomon, Todd M Bauer, Sai-Hong Ignatius Ou, et al.The Lancet. Oncology|January 21, 2014
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trialYi-Long Wu, Caicun Zhou, Cheng-Ping Hu, et al.Pageof 224